# A Study of Orally Administered IPG7236 in Healthy Adult Participants

> **NCT05288543** · PHASE1 · TERMINATED · sponsor: **Nanjing Immunophage Biotech Co., Ltd** · enrollment: 63 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** IPG7236- Single ascending dose
- **DRUG:** IPG7236- Multiple ascending dose
- **OTHER:** Placebo (Part A)

## Key facts

- **NCT ID:** NCT05288543
- **Lead sponsor:** Nanjing Immunophage Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-07
- **Primary completion:** 2023-03-31
- **Final completion:** 2025-11-26
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288543, "A Study of Orally Administered IPG7236 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05288543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*